Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
GAITHERSBURG, Md., Nov. 01, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a conference call at 5:00 pm (Eastern Time). In the press release and on the conference call, the Company will discuss its financial results for the quarter and year-to-date periods of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: |
| Dial in number: (855) 766-6521 |
| International dial in: (262) 912-6157 |
| Conference ID: 29486767 |
| Live Webcast Information: |
| Visit http://edge.media-server.com/m/p/89rbd7rh/lan/en for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website www.emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
